Posters

Transient macular edema after intracameral injection of a standard dose of cefuroxime during phacoemulsification surgery: a report of three cases

Poster Details

First Author: A.Saitta ITALY

Co Author(s):    L. Avoni   A. Bratu   P. Rossini   A. Volinia   D. D'Eliseo        

Abstract Details

Purpose:

Macular edema and detachment at the first day after an uneventful cataract surgery is very rare, and has been reported previously with the use of high concentrations of intra-cameral cefuroxime. However, we hereby reported three cases of macular edema with extensive serous retinal detachment the first day after an uneventful phacoemulsification with intra-cameral injection of a standard dose of cefuroxime during the procedure.

Setting:

Department of Ophthalmology, 'Santa Maria delle Croci' Hospital, Ravenna, Italy

Methods:

Three eyes of three patients without any preexisting ocular comorbidity underwent an uneventful phacoemulsification surgery and 1 mg/0.1 ml of cefuroxime solution was injected into the anterior chamber at the end of the procedure. Combination of nonsteroidal anti-inflammatory drugs and corticosteroids was applied in all cases topically as routine anti-inflammation treatment after phacoemulsification.

Results:

Visual dysfunction secondary to macular edema with extensive serous retinal detachment around macula and optic disc area was observed the first day after surgery in all cases. Without surgical intervention, a quick recovery of the macular edema and retinal detachment was observed by spectral domain optical coherence tomography 1 week later (range 3-10 days) in all cases. Visual recovery was complete. No recurrence of macular edema or retinal detachment was noticed until the last follow-up (6 months after surgery).

Conclusions:

We presumed that intracameral injection of cefuroxime sodium at a standard dose of 1 mg/0.1 mL may be associated with transient macular edema and diminished visual acuity, resolving largely within 1 week. Routine anti-inflammatory treatment is sufficient and do not require excessive interventions.

Financial Disclosure:

NONE